Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

Completed

• Conditions: Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
• Interventions: Drug: Anti-PD-1 or anti-PD-L1

• Registration Number: NCT04609930
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-10-26
• Study First Submitted QC: 2020-10-26
• Study Start: 2020-10-30
• Study First Posted: 2020-10-30
• Primary Completion: 2021-08-31
• Study Completion: 2021-08-31
• Status Verified: 2021-11
• Last Update Submitted: 2021-12-22
• Last Update Posted: 2021-12-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 143

Inclusion Criteria

• Electronic patient file "DxCare" at the University Hospitals of Montpellier
• Patient has received anti-PD-1 immunotherapy --AND/OR -- anti-PD-L1 immunotherapy according to central pharmacy records

Exclusion Criteria

• No mention of % eosinophilia in the patient file

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
The study population	Anti-PD-1 or anti-PD-L1	Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1

Primary Outcome Measures

Name	Time	Method
Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1	Before treatment (before day 0) versus after (12 months)

Secondary Outcome Measures

Name	Time	Method
Indication leading to anti-PD-1 and/or anti-PD-L1 immunotherapies	Day 0	Name of pathology
Age (years)	Day 0
Sex (male/female)	Day 0

Trial Locations

Locations (1)

UH Montpellier; 🇫🇷 Montpellier, France